{"id":"cap-1002","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Pericardial effusion"},{"rate":null,"effect":"Cardiac arrhythmias"}]},"_chembl":{"chemblId":"CHEMBL5991048","moleculeType":null,"molecularWeight":"502.49"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CAP-1002 consists of cultured cardiosphere-derived cells (CDCs) derived from donor heart tissue that secrete cardioprotective factors and anti-inflammatory cytokines. These cells promote angiogenesis, reduce fibrosis, and modulate the immune response to support recovery of damaged myocardium. The therapy works through paracrine mechanisms rather than direct cell engraftment or differentiation.","oneSentence":"CAP-1002 is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and regeneration through paracrine signaling and immunomodulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:07:40.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Duchenne muscular dystrophy (DMD) with cardiac involvement"},{"name":"Acute myocarditis"}]},"trialDetails":[{"nctId":"NCT05126758","phase":"PHASE3","title":"A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Capricor Inc.","startDate":"2022-06-22","conditions":"Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic","enrollment":106},{"nctId":"NCT04428476","phase":"PHASE2","title":"Open-label Extension of the HOPE-2 Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Capricor Inc.","startDate":"2020-08-05","conditions":"Duchenne Muscular Dystrophy","enrollment":13},{"nctId":"NCT03406780","phase":"PHASE2","title":"A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy","status":"COMPLETED","sponsor":"Capricor Inc.","startDate":"2018-04-04","conditions":"Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic","enrollment":20},{"nctId":"NCT04623671","phase":"PHASE2","title":"Intravenous Infusion of CAP-1002 in Patients With COVID-19","status":"COMPLETED","sponsor":"Capricor Inc.","startDate":"2020-11-15","conditions":"Covid19","enrollment":55},{"nctId":"NCT02485938","phase":"PHASE2","title":"HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)","status":"COMPLETED","sponsor":"Capricor Inc.","startDate":"2016-01-07","conditions":"Duchenne Muscular Dystrophy, Cardiomyopathy","enrollment":25},{"nctId":"NCT02941705","phase":"PHASE2","title":"Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-07-12","conditions":"Congestive Heart Failure, Heart Failure, Diastolic","enrollment":27},{"nctId":"NCT06304064","phase":"PHASE2","title":"Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)","status":"COMPLETED","sponsor":"Capricor Inc.","startDate":"2018-06-21","conditions":"Duchenne Muscular Dystrophy","enrollment":8},{"nctId":"NCT01458405","phase":"PHASE1, PHASE2","title":"Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration","status":"TERMINATED","sponsor":"Capricor Inc.","startDate":"2012-11-13","conditions":"Myocardial Infarction","enrollment":135},{"nctId":"NCT03145298","phase":"PHASE1","title":"ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-10-01","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":26},{"nctId":"NCT04338347","phase":"","title":"CAP-1002 in Severe COVID-19 Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Capricor Inc.","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT02293603","phase":"PHASE1","title":"Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)","status":"UNKNOWN","sponsor":"Capricor Inc.","startDate":"2014-11","conditions":"Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cardiosphere-Derived Cells","CDCs","deramiocel","Allogeneic Cardiosphere-Derived Cells"],"phase":"phase_2","status":"active","brandName":"CAP-1002","genericName":"CAP-1002","companyName":"Capricor Inc.","companyId":"capricor-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAP-1002 is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and regeneration through paracrine signaling and immunomodulation. Used for Duchenne muscular dystrophy (DMD) with cardiac involvement, Acute myocarditis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}